# Presentation: 532463

## Director’s Report to the

**Director’s Report to the**
**National Advisory Council**
**on Drug Abuse**

**     ****May 17, 2005**

## Budget Update

**Budget Update**

**Recent NIDA Activities**
** ****& Events**

**Policy Issues**

## Slide 3

## NIDA  BUDGET

**(Thousands)**

**Increase Over**** Prior Year**

**AIDS**

**TOTAL**

**NonAIDS**

## Slide 5

## Sets out broad prohibitions regarding...

***Sets out broad prohibitions regarding...***
**	****	****	****Outside activities**
**	****	****	****Holdings**
**	****	****	****Awards**

**         ****NEW Supplemental Ethics Regulation**
**        ****That Affects ALL NIH Employees **

***Current Status: ***
**Pending Response From Employees**

## Recent NIDA Activities

**Recent NIDA Activities**
**& Events**

## NIDA PAs and RFAs Just Issued

**Collaborative Multisite Research in Addiction (COMRAD) (PA-05-067) **
**Minority Institutions’ Drug Abuse Research Development Program (MIDARP) (PAR-05-069) **
**Drug Abuse Dissertation Research: Epidemiology, **
**     ****Prevention, Treatment, Services and Women and Sex/**
**     ****Gender Differences (PAR-05-083) **
**Inhalant Abuse: Supporting Broad-Based Research Approaches (PA-05-099) **
**Strategic Program for Innovative Research on Drug **
**     ****Addiction Pharmacotherapy (SPIRDAP) (RFA-DA-05-009) **

**NIDA PAs and RFAs Just Issued**

## 13 New PAs and 4 New RFAs

**Foci include:**
**Neurobiology**
**Co-morbidity**
**HIV/AIDS**
**Brain Development**
**Research Training**
**Software/Biomedical Computing**
**International Collaboration**

**PAs and RFAs Recently Issued With**
**Other NIH Components/Agencies**

## NIDA

**NIDA**

**National Institute ****on**** Drug Abuse**

**Special Populations Office**

**Division of **
**Basic Neurosciences**
**& Behavior Research**

**Office of**
**Extramural **
**Affairs**

**Office of Planning**
**& Resource**
** ****Management**

**Office of **
**Science Policy & **
**Communications**

** ****Intramural **
**Research**
**Program**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Division of**
**Pharmacotherapies &**
**Medical Consequences**
**of Drug Abuse**

**Center for the**
**Clinical Trials **
**Network**

**Teresa Levitin, PhD**

**Laura Rosenthal**

**Timothy Condon, PhD**

**Betty Tai, PhD**

**David Shurtleff, PhD**

**Frank Vocci, PhD**

**Wilson Compton, MD, MPE**

**Barry Hoffer, MD, PhD**

**Office of the Director**

**Nora D. Volkow, MD**

** ****Director**

**Timothy P. Condon, Ph.D.**

**Deputy Director**

**Laura S. Rosenthal**

**Associate Director**
**for Management**

** ****Division of Clinical**
**Neuroscience, **
**Development &**
**Behavioral**
**Treatment**

**Joseph Frascella, PhD**

**Director, AIDS Research**

**HIV/AIDS Research**

**Dr. Jacques Normand **
**Will Provide an Update **

## NIDA

**NIDA**

**National Institute ****on**** Drug Abuse**

**Special Populations Office**

**Division of **
**Basic Neurosciences**
**& Behavior Research**

**Office of**
**Extramural **
**Affairs**

**Office of Planning**
**& Resource**
** ****Management**

**Office of **
**Science Policy & **
**Communications**

** ****Intramural **
**Research**
**Program**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Division of**
**Pharmacotherapies &**
**Medical Consequences**
**of Drug Abuse**

**Center for the**
**Clinical Trials **
**Network**

**Teresa Levitin, PhD**

**Laura Rosenthal**

**Timothy Condon, PhD**

**Betty Tai, PhD**

**David Shurtleff, PhD**

**Frank Vocci, PhD**

**Wilson Compton, MD, MPE**

**Barry Hoffer, MD, PhD**

**Office of the Director**

**Nora D. Volkow, MD**

** ****Director**

**Timothy P. Condon, Ph.D.**

**Deputy Director**

**Laura S. Rosenthal**

**Associate Director**
**for Management**

** ****Division of Clinical**
**Neuroscience, **
**Development &**
**Behavioral**
**Treatment**

**Joseph Frascella, PhD**

**Director, AIDS Research**

**Special Population/**
**Health Disparities**

**Dr. Jose Szapocznik **
**Will Report on **
**Minority Health **
**Disparities Workgroup **
**Findings & Recommendations**

## NIDA

**NIDA**

**National Institute ****on**** Drug Abuse**

**Special Populations Office**

**Division of **
**Basic Neurosciences**
**& Behavior Research**

**Office of**
**Extramural **
**Affairs**

**Office of Planning**
**& Resource**
** ****Management**

**Office of **
**Science Policy & **
**Communications**

** ****Intramural **
**Research**
**Program**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Division of**
**Pharmacotherapies &**
**Medical Consequences**
**of Drug Abuse**

**Center for the**
**Clinical Trials **
**Network**

**Teresa Levitin, PhD**

**Laura Rosenthal**

**Timothy Condon, PhD**

**Betty Tai, PhD**

**David Shurtleff, PhD**

**Frank Vocci, PhD**

**Wilson Compton, MD, MPE**

**Barry Hoffer, MD, PhD**

**Office of the Director**

**Nora D. Volkow, MD**

** ****Director**

**Timothy P. Condon, Ph.D.**

**Deputy Director**

**Laura S. Rosenthal**

**Associate Director**
**for Management**

** ****Division of Clinical**
**Neuroscience, **
**Development &**
**Behavioral**
**Treatment**

**Joseph Frascella, PhD**

**Director, AIDS Research**

**CCTN**

## Applications Reviewed 

**Application Receipt Date: October 14, 2004**
**        ****15 Applications Received -- 4 New          **
***Applications Reviewed ***
***13 Scored***

**The National Drug Abuse Treatment**
**Clinical Trials Network**
**(RFA-DA-05-001)**
***Issued July 7, 2004***

## CTN Clinical Coordinating Center

**Contract Awarded to**
**The EMMES Corporation**

**CTN Data and Statistics Center (DSC)**
**Contract Awarded to**
**Duke Clinical Research Institute (DCRI)**

## Update on New CTN Protocols

**    ****Therapies (START):**** compare  the effect of **
**    ****buprenorphine/naloxone and methadone on **
**    ****liver function   *****10 sites, January 2006***
**  ****Randomized Controlled Trial of Methylphenidate**
**    ****in Adolescents with ADHD and Substance Use**
**    ****Disorders  *****12 sites,***** *****Fall 2005***
**  ****Methylphenidate in Maintaining Abstinence in**
**    ****Smokers with ADHD  *****6 sites, Fall 2005***
**  ****Prescription Opioid Addiction Treatment**
**    ****Study (POATS)   *****~ 12 sites, Fall 2005***** **

**Update on New CTN Protocols**

## NIDA

**NIDA**

**National Institute ****on**** Drug Abuse**

**Special Populations Office**

**Division of **
**Basic Neurosciences**
**& Behavior Research**

**Office of**
**Extramural **
**Affairs**

**Office of Planning**
**& Resource**
** ****Management**

**Office of **
**Science Policy & **
**Communications**

** ****Intramural **
**Research**
**Program**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Division of**
**Pharmacotherapies &**
**Medical Consequences**
**of Drug Abuse**

**Center for the**
**Clinical Trials **
**Network**

**Teresa Levitin, PhD**

**Laura Rosenthal**

**Timothy Condon, PhD**

**Betty Tai, PhD**

**David Shurtleff, PhD**

**Frank Vocci, PhD**

**Wilson Compton, MD, MPE**

**Barry Hoffer, MD, PhD**

**Office of the Director**

**Nora D. Volkow, MD**

** ****Director**

**Timothy P. Condon, Ph.D.**

**Deputy Director**

**Laura S. Rosenthal**

**Associate Director**
**for Management**

** ****Division of Clinical**
**Neuroscience, **
**Development &**
**Behavioral**
**Treatment**

**Joseph Frascella, PhD**

**Director, AIDS Research**

**DPMCDA**

## REPORT 

*REPORT *
*from the** *
*Medications Development Program *
*Work Group*
*2005*
**National Institute**
**on Drug Abuse**
- National Institutes of Health
- U.S. Department of Health and Human Services

## Committee Members

**Committee Members**

**Bankole Johnson, M.D., Ph.D.**
**  ****UT San Antonio**
**Peter Kalivas, Ph.D.**
**  ****Med U South Carolina**
**Herb Kleber, M.D.**
**  ****Columbia University**
**George Koob, Ph.D.**
**  ****Scripps Research Institute**
**Mary Jeanne Kreek, M.D.**
**  ****Rockefeller University**

**Bertha Madras, Ph.D.**
**  ****Harvard Medical School**
**Eric Nestler, M.D., Ph.D.**
**  ****Southwestern University**
**Scott Reines, M.D., Ph.D.**
**  ****Johnson & Johnson**
**Ray White, Ph.D.**
**  ****UC San Francisco**

***Science Writer (Contractor)***
**Jennifer Elcano, M.A.**

***NIDA Staff***
**Denise Pintello, Ph.D. M.S.W.**

## Summary of Workgroup Recommendations

**Internal Organization**
**Create a SAB to advise on internal efficiencies & decision**
**making**
**Interactions with other NIDA Divisions**
**Restructure relationships, especially with CCTN and IRP**
**Interactions with Pharmaceutical Companies**
**Establish NIDA as an asset to pharma for abuse liability**
**screening and clinical trials**
**Role of Genetics**
**Develop a human genetic resource via collaborations **
**between MDP and CCTN**

**Summary of Workgroup Recommendations**

## Medications Development Scientific Workgroup 

**Members**

**Medications Development Scientific Workgroup **

***First Meeting: ***
**Hyatt Regency Hotel**
**Bethesda, MD**
**March 21-22, 2005**

**Kenneth Davis, M.D.**
**Lisa H. Gold, Ph.D.****	****	****	**
**Suneel Gupta, Ph.D.****	****	****	**
**Bankole Johnson, M.D., Ph.D.**
**Peter Kalivas, Ph.D. **
**Herb Kleber, M.D.**
**Thomas R. Kosten, M.D.****	**
**Susan Learned-Coughlin, Pharm.D, Ph.D.**
**Bertha Madras, Ph.D.**
**Eric Nestler, M.D., Ph.D.**
**Charles P. O’Brien, M.D., Ph.D.**
**Kenner Rice, Ph.D.**

##    Interactions With Other NIDA Components

**    ****Therapies (START) Study (with CCTN)**
**  ****Institute-wide Workgroup with Representatives **
**     ****from CCTN, IRP and all Extramural Divisions **

**   ****Interactions With Other NIDA Components**

## NIDA

**NIDA**

**National Institute ****on**** Drug Abuse**

**Special Populations Office**

**Division of **
**Basic Neurosciences**
**& Behavior Research**

**Office of**
**Extramural **
**Affairs**

**Office of Planning**
**& Resource**
** ****Management**

**Office of **
**Science Policy & **
**Communications**

** ****Intramural **
**Research**
**Program**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Division of**
**Pharmacotherapies &**
**Medical Consequences**
**of Drug Abuse**

**Center for the**
**Clinical Trials **
**Network**

**Teresa Levitin, PhD**

**Laura Rosenthal**

**Timothy Condon, PhD**

**Betty Tai, PhD**

**David Shurtleff, PhD**

**Frank Vocci, PhD**

**Wilson Compton, MD, MPE**

**Barry Hoffer, MD, PhD**

**Office of the Director**

**Nora D. Volkow, MD**

** ****Director**

**Timothy P. Condon, Ph.D.**

**Deputy Director**

**Laura S. Rosenthal**

**Associate Director**
**for Management**

** ****Division of Clinical**
**Neuroscience, **
**Development &**
**Behavioral**
**Treatment**

**Joseph Frascella, PhD**

**Director, AIDS Research**

**DBNBR**

## NIH IC Directors’ Roadmap Retreat

***April 20, 2005***

**  ****Molecular Libraries**

## NIH Neuroscience Blueprint

**NIH Neuroscience Blueprint**

**Project Team                 ****	****Lead IC**
**GENSAT expansion ****	****  ****	****NINDS**
**Neurobiology of Disease**
**  ****Training Supplements    ****	****NIMH**
**Neuroscience Inventory   ****	****NIDA**

**FY 2005 (****Tap =  0.15%)****       **

** ****Neuroimaging Training**
** ****Computational Neuroscience**
** ****Neurobiology of Disease**

**FY 2006**** (****Tap =  0.30%)****       **

**Project Team              Lead IC**
**Core Grants****	**** ****	**** NINDS**
**Neuromouse****	****	**** NIMH**
**Training    ****	****	**** NIDA**

## Neuroscience Blueprint ‘06 

**Beth Babecki, NIDA**
**Robert Baughman, NINDS**
**Allison Chausmer, NIDA**
**Alison Cole, NIGMS**
**Nancy Desmond, NIMH**
**Gayathri J Dowling, NIDA**
**Dennis Glanzman, NIMH**
**Lindsey Grandison, NIAAA**
**Steven Grant, NIDA**
**Kevin Hardwick, NIDCR**
**Deborah Henken, NICHD**
**Chyren Hunter, NEI**
**Henry Khachaturian, NIBIB**
**Teresa Levitin, NIDA**
**Yuan Liu, NINDS**
**Susan Molchan, NIA**

**Andrew Monjan, NIA**
**Juanita Nelson, NIDA**
**Nancy Pearson, NCCAM**
**Nancy Pilotte, NIDA**
**Suman Rao King, NIDA**
**Charles Sharp, NIDA**
**Carol Shreffler, NIEHS**
**David Shurtleff, NIDA**
**Karen Skinner, NIDA**
**Roger Sorensen, NIAAA**
**Daniel Sklare, NIDCD**
**Mark Swieter, NIDA**
**Meredith Temple-O’Connor, NIBIB**
**Susan Volman, NIDA**
**Kenneth Whang, NSF**

**Susan Weiss, NIDA, Co-Chair**

**Laurence Stanford, NIDA, Co-Chair**

**Neuroscience Blueprint ‘06 **
**Training Project Team **

## Training Subgroups

**  ****Neurobiology of Disease **
**  ****Computational Neuroscience**

**Training Subgroups**

## Interdisciplinary Predoctoral Trainingin Neuroscience Imaging: Integrating First Principles and Application

_***Purpose:***_
**	****To develop interdisciplinary, predoctoral training programs that integrate imaging technologies, neuroscience applications, and the underlying neurobiological principles with the aim of creating a**
**    ****cadre of scientists who can optimally utilize imaging technologies to address neuroscience questions**

## Neurobiology of Disease: 

**Train MD, PhD and other scientists in the multiple theories, techniques, analytic strategies and objectives of research on the neurobiology**
**of disease **

**Neurobiology of Disease: **
**Training in Translational Research **
**in Neuroscience **

## Computational Neuroscience: 

**From Model to Biology and Back Again**** **

_***Purpose:***_
**  ****Interdisciplinary training of pre- and postdoctoral **
**  ****fellows competent in the theories, principles and**
**  ****application of the physical, computer, or **
**  ****mathematical sciences to experimental neuroscience**

## NIDA

**NIDA**

**National Institute ****on**** Drug Abuse**

**Special Populations Office**

**Division of **
**Basic Neurosciences**
**& Behavior Research**

**Office of**
**Extramural **
**Affairs**

**Office of Planning**
**& Resource**
** ****Management**

**Office of **
**Science Policy & **
**Communications**

** ****Intramural **
**Research**
**Program**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Division of**
**Pharmacotherapies &**
**Medical Consequences**
**of Drug Abuse**

**Center for the**
**Clinical Trials **
**Network**

**Teresa Levitin, PhD**

**Laura Rosenthal**

**Timothy Condon, PhD**

**Betty Tai, PhD**

**David Shurtleff, PhD**

**Frank Vocci, PhD**

**Wilson Compton, MD, MPE**

**Barry Hoffer, MD, PhD**

**Office of the Director**

**Nora D. Volkow, MD**

** ****Director**

**Timothy P. Condon, Ph.D.**

**Deputy Director**

**Laura S. Rosenthal**

**Associate Director**
**for Management**

** ****Division of Clinical**
**Neuroscience, **
**Development &**
**Behavioral**
**Treatment**

**Joseph Frascella, PhD**

**Director, AIDS Research**

**DCNDBT**

##        MRI Study of Normal Brain Development(N=500)

**Create a ****database**** of behavioral and brain MRI development data for 0-18 years**
**Analyze ****structural-behavioural relationships**
**Develop technique for ****dissemination**** of results**

## Neurobiology of Behavioral Treatment: 

**Neurobiology of Behavioral Treatment: **
**Recovery of Brain Structure and Function**
**RFA-DA-05-006**

***22 Applications Received***

**Consequences of Drug Abuse & Alcohol**
**Exposure on Brain & Behavioral Development**
**RFA-DA-05-007**

***Issued with NIAAA -- 36 Applications Received***

**HIV & Drug Abuse Interventions Among **
**Pregnant Women in Drug Abuse Treatment**
**RFA-DA-05-008**

*** ******16 Applications Received***

## NIDA

**NIDA**

**National Institute ****on**** Drug Abuse**

**Special Populations Office**

**Division of **
**Basic Neurosciences**
**& Behavior Research**

**Office of**
**Extramural **
**Affairs**

**Office of Planning**
**& Resource**
** ****Management**

**Office of **
**Science Policy & **
**Communications**

** ****Intramural **
**Research**
**Program**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Division of**
**Pharmacotherapies &**
**Medical Consequences**
**of Drug Abuse**

**Center for the**
**Clinical Trials **
**Network**

**Teresa Levitin, PhD**

**Laura Rosenthal**

**Timothy Condon, PhD**

**Betty Tai, PhD**

**David Shurtleff, PhD**

**Frank Vocci, PhD**

**Wilson Compton, MD, MPE**

**Barry Hoffer, MD, PhD**

**Office of the Director**

**Nora D. Volkow, MD**

** ****Director**

**Timothy P. Condon, Ph.D.**

**Deputy Director**

**Laura S. Rosenthal**

**Associate Director**
**for Management**

** ****Division of Clinical**
**Neuroscience, **
**Development &**
**Behavioral**
**Treatment**

**Joseph Frascella, PhD**

**Director, AIDS Research**

**DESPR**

## Sponsored by 

**Effectively Breaking the Cycle **
**of Drugs and Crime:**
**Research & Treatment Provide the Answers**
***Sponsored by ***
***The Friends of NIDA***
**March 15, 2005**

## 6 studies in the field focused on:
Reducing HIV risk behavior
Screening for mental illness
Transitioning from prison to community
2 juvenile justice studies being developed
Community re-entry and HIV risk behaviors
2 HIV studies being developed:
Men
Women

**Reducing HIV risk behavior**
**Screening for mental illness**
**Transitioning from prison to community**
**2 juvenile justice studies being developed**
**Community re-entry and HIV risk behaviors**
**2 HIV studies being developed:**
**Men**
**Women**

**www.cjdats.org**

**CJ-DATS Update****Criminal Justice Drug Abuse Treatment Studies**

## CASA 

**Primary Care**
** ****Meeting**

## Screening and Intervention for Youth in

**Screening and Intervention for Youth in**
**Primary Care Settings**
**RFA-DA-04-006**

***Issued with SAMHSA, HRSA and AHCPR***

**Purpose:  Expand the role of primary care in addressing problem drug use—especially marijuana—among youth in the pre-dependency phase of drug abuse.**
**36 applications**
_**7 awards made in September, 2004**_**:**
**	****4 Behavioral Treatment Research**
**	****2 Health Services Research**
**	****1 Prevention Research**

## Congressional Hearings

**Consequences of the Abuse of **
**Anabolic Steroids **
***Testimony before the Committee on ***
***Government Reform -- March 17, 2005***
**Fiscal Year 2006 Budget Request**
***Testimony before the:***
***House Subcommittee on Labor-HHS-Education Approp. -- March 9, 2005***
***Senate Subcommittee on Labor-HHS-Education Approp. -- April 6, 2005***
**Methamphetamine Abuse**
***Testimony before the Senate Subcommittee on Labor, HHS, Education, &***
***Related Agencies -- Committee on Appropriations -- April 21, 2005***
**Substance Abuse and Mental Health Research & Services**
***Testimony before the House Subcommittee on Labor, HHS & Education***
***Committee on Appropriations -- April 27, 2005***

## NIDA Also Co-sponsored or Had Involvement in... 

**Treatment**
**March 23, 2005**

**2005 SAMHSA/NIDA Buprenorphine Summit **
**April 11-12, 2005**** **

**Impact of Drug Formulation on Abuse Liability,**
**Safety and Regulatory Decisions (CPDD)**
**April 19-20, 2005**
**Methamphetamine Research Workgroup Meeting**
**March 9-10, 2005 **
**PRIDE 2005 – A Special Research Track from NIDA**
**April 6-9, 2005**

***NIDA Also Co-sponsored or Had Involvement in... ***

## 9th Annual 

**9****th**** Annual **
**PRISM Awards Event**
**Beverly Hills Hotel**
**April 28, 2005**
**Event will air as a **
**one-hour TV special**
**on FX Network **
**September 4, 2005 at 5:00pm**

## Cannabis Dependence Treatment:

**Cannabis Dependence Treatment:**
**Where We Are, Where We Are Going**
**Issue Workshop **
**Tuesday, May 24, 2005  -- 11:00 am to 12:30 pm**
**Increases in Opioid Analgesic Abuse: **
**Concerns and Strategies**
**Symposium **
**Tuesday, May 24, 2005 -- 2:00 pm to 5:00 pm**
** **
**New Scientific Advances in the **
**Neurobiology of Behavior**
**Symposium **
**Wednesday, May 25, 2005 -- 2:00 pm to 5:00 pm**
**Neurobiology of Compulsive **
**Reward-Seeking**
**Symposium **
**Thursday, May 26, 2005 -- 2:00 pm to 5:00 pm**

## NIDA-Sponsored Events at CPDD 2005  

**NIDA-Sponsored Events at CPDD 2005  **

**International Forum *****(June 17******th - ******19******th******)***
**Review & Evaluation of NIDA Targets for**
** ****Potential NIH Roadmap Library **
** ****Screening Efforts **
** ****NIDA Tutorials **
** ****Translating Basic Research from Neural,**
**  ****Behavioral, & Social Sciences to Prevention**
**Proteomics & Its Application to Drug Abuse**
**Mice Tales: Novel Insights Into **
**  ****Understanding Addiction**
**NIDA Training Mixer**
**NIDA/CPDD Grant-writing Workshop**
**Pharmacogenetics & Drug Abuse Research**
** **

***June 17th***

***June 18th***

***June 20th***

***June 21st***

***June 22nd***

**A record number of posters from CTN research**
**will be presented at this year’s meeting**

##   NIDA

**    ****Commissioned articles**
**    ****highlighting current progress**
**    ****in the neurobiology**
**    ****of feeding regulation, **
**    ****energy metabolism and obesity**
***             ******Sponsored by the***** **
**            ****Obesity Research**
**            ****Task Force of the**
**    ****National Institutes of Health**
** **

**  ****NIDA**
**  ****NIDDK**
**  ****NIAAA**
**  ****NHLBI**

## Slide 45